Related references
Note: Only part of the references are listed.A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
P. J. Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy
E. P. Tamm et al.
ABDOMINAL IMAGING (2006)
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
CH Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells
AD Yang et al.
CANCER RESEARCH (2006)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines
JS Wey et al.
CANCER (2005)
Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12
T Rich et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
